Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

Pels, Hendrik; Schmidt‐Wolf, Ingo G.H.; Glasmacher, Axel; Schulz, H.; Engert, Andreas; Diehl, Volker; Zellner, Anton; Schackert, Gabriele; Reichmann, Heinz; Kroschinsky, Frank; Vogt‐Schaden, Marlies; Egerer, Gerlinde; Bode, Udo; Schaller, Carlo; Deckert, Martina; Fimmers, Rolf; Helmstaedter, Christoph; Atasoy, Aslihan; Klockgether, Thomas; Schlegel, Uwe

doi:10.1200/jco.2003.04.056

Cited by 387 publications

(289 citation statements)

References 30 publications

Supporting

Mentioning

260

Contrasting

Unclassified

Order By: Relevance

“…Treatment consisted of six chemotherapy cycles separated by two weeks between each cycle. In contrast to the previously published pilot / phase II trial [3], neither intraventricular nor intrathecal therapy was administered. Details of the protocol are given in Table 1.…”

Section: Treatment Protocol and Study Designmentioning

confidence: 99%

“…[6,7] Patients with lymphoma at presentation involving sites other than the brain, meninges, cerebrospinal fluid (CSF) or the eyes were not included. Patients to be enrolled in this trial were stratified for age to make sure all patients < 60 years of age received the same systemic chemotherapy as previously applied in the former pilot/phase II trial [3] but no intraventricular treatment, whereas patients 60 to 75 years of age received a modified regimen. Therefore, only patients < 60 years of age are considered in this analysis.…”

Section: Inclusion Criteriamentioning

confidence: 99%

“…The initial protocol has been applied in a pilot/phase II trial including intraventricular therapy with MTX, Ara-C and dexamethasone during each cycle [3]. The clinical trial cited here was an open-label, non-randomized study.…”

Section: Treatment Protocol and Study Designmentioning

confidence: 99%

“…In 2003 we have reported the results of a pilot/phase II study on a novel combined systemic and intraventricular chemotherapy regimen without radiotherapy in 65 consecutive patients. [3] The overall response rate was 71% for the whole group, median time to treatment failure (TTF) 21 months, and median overall survival (OS) 50 months. Results were significantly better in patients < 60 years of age with a 86% overall response rate and a 75% survival fraction at five years.…”

Section: Introductionmentioning

confidence: 98%

“…However, Ommaya reservoir infection occurred in 19% of the whole group, and represented a serious complication in some patients, resulting in interruption or delay of chemotherapy. [3] Therefore, and considering data from the literature questioning the benefit of intraventricular chemotherapy in PCNSL [4,5], we treated patients with systemic therapy only in a subsequent phase II trial initiated in 08/2003.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

et al. 2008

Self Cite

View full text Add to dashboard Cite

and 5) and cytarabine (Ara-C; cycles 3,6) based systemic therapy including dexamethasone, vinca-alkaloids, ifosfamide and cyclophosphamide.Results: Study accrual was prematurely stopped in 11/05 due to a high rate of early relapses.Seventeen/18 patients were assessable for response: Nine (53%) achieved complete response (CR), two (12%) complete response/unconfirmed (CRu), two (12%) partial response (PR), four (24%) showed progressive disease (PD); one treatment was stopped due to toxicity.Median follow-up is 23 months; median response duration was only ten months in responding patients and median time to treatment failure (TTF) eight months in the whole group; median overall survival (OS) has not been reached. Systemic toxicity was mainly hematologic.Conclusions: In PCNSL patients < 60 years polychemotherapy without intraventricular treatment results in a high response rate, but is associated with early relapses in the majority of cases. This is in contrast to the results achieved with the same protocol but with intraventricular treatment.

show abstract

Section: Treatment Protocol and Study Designmentioning

confidence: 99%

Section: Inclusion Criteriamentioning

confidence: 99%

Section: Treatment Protocol and Study Designmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

Delayed Neurotoxicity in Primary Central Nervous System Lymphoma

et al. 2005

View full text Add to dashboard Cite

Background: Treatment for primary central nervous lymphoma (PCNSL) with chemotherapy and radiotherapy has resulted in improved survival, but some patients develop neurologic deterioration that represents a treatment-related toxic effect. This delayed neurotoxicity has been poorly defined in the literature, and the underlying mechanisms are unknown. Objective: To describe the clinical findings, time course, and pathophysiologic mechanisms associated with neurotoxicity in an attempt to generate hypotheses for future studies that address prevention and treatment of this complication of successful PCNSL therapy.

show abstract